Choroideremia Treatment Market Trends

  • Report ID: 5519
  • Published Date: Jan 03, 2025
  • Report Format: PDF, PPT

Choroideremia Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing advancement in medical technology - One of the main factors propelling the market for choroideremia treatments is advancements in healthcare technologies. Numerous advancements over the past several years have resulted in novel choroideremia therapy options. 

    These advancements not only expanded the pool of treatments available but also improved accessibility to them. Patients can now better manage their symptoms and improve their quality of life because of the medications' increased efficacy.

  • Favorable government policies - Globally, governments are becoming more proactive in fostering the development and availability of treatments for rare diseases such as choroideremia. Patients now have more access to medicines and treatments that can help regulate their symptoms as a result of this assistance, which has also stimulated innovation and investment in the field.

Challenges

  • Complex disease pathology - Choroideremia is caused by mutations in the CHM gene that affect the production of a protein essential for the proper function of the retina. The complex interplay between genetics, cellular processes, and visual function makes it challenging to develop effective therapies.

  • Side effects and safety issues associated with the treatment.

  • Limited access to specialty is another factor posing limitations on the choroideremia treatment market growth in the near future.

Base Year

2024

Forecast Year

2025-2037

CAGR

4.8%

Base Year Market Size (2024)

USD 9.43 billion

Forecast Year Market Size (2037)

USD 17.35 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of choroideremia treatment is evaluated at USD 9.81 billion.

The choroideremia treatment market size was over USD 9.43 billion in 2024 and is poised to exceed USD 17.35 billion by 2037, witnessing over 4.8% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of choroideremia and growing advancement in medical technology will boost the market growth.

North America industry is set to hold largest revenue share of 35% by 2037, due to rising substantial innovation in healthcare infrastructure in the region.

The major players in the market are Biogen, Copernicus Therapeutics, Inc., 4D Molecular Therapeutics, Wize Pharma Inc., Retina Implant AG, Hoffmann-La Roche Ltd, and others.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos